- Home
- IMPP vs DTIL Comparison
IMPP vs DTIL Comparison
Compare IMPP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | DTIL |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.7M | 197.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMPP | DTIL |
|---|---|---|
| Price | $4.51 | $10.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.40 |
| AVG Volume (30 Days) | ★ 334.3K | 213.9K |
| Earning Date | 12-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $86.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $3.53 |
| 52 Week High | $6.57 | $9.62 |
Technical Indicators
Market Signals| Indicator | IMPP | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 80.44 |
| Support Level | $4.04 | $6.12 |
| Resistance Level | $5.03 | N/A |
| Average True Range (ATR) | 0.19 | 0.78 |
| MACD | -0.06 | 0.39 |
| Stochastic Oscillator | 22.89 | 84.04 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).